70 related articles for article (PubMed ID: 26549592)
1. A new way to target p53-defective colorectal cancer.
Liu Y; Wang L; Lu X
Future Oncol; 2015; 11(23):3101-4. PubMed ID: 26549592
[No Abstract] [Full Text] [Related]
2. TP53 loss creates therapeutic vulnerability in colorectal cancer.
Liu Y; Zhang X; Han C; Wan G; Huang X; Ivan C; Jiang D; Rodriguez-Aguayo C; Lopez-Berestein G; Rao PH; Maru DM; Pahl A; He X; Sood AK; Ellis LM; Anderl J; Lu X
Nature; 2015 Apr; 520(7549):697-701. PubMed ID: 25901683
[TBL] [Abstract][Full Text] [Related]
3. Colorectal cancer: POLR2A deletion with TP53 opens a window of opportunity for therapy.
Errico A
Nat Rev Clin Oncol; 2015 Jul; 12(7):374. PubMed ID: 25985938
[No Abstract] [Full Text] [Related]
4. Colorectal cancer: A circuitous way to target p53.
Seton-Rogers S
Nat Rev Cancer; 2015 Jun; 15(6):318-9. PubMed ID: 25971675
[No Abstract] [Full Text] [Related]
5. Drug resistance and new therapies in colorectal cancer.
Van der Jeught K; Xu HC; Li YJ; Lu XB; Ji G
World J Gastroenterol; 2018 Sep; 24(34):3834-3848. PubMed ID: 30228778
[TBL] [Abstract][Full Text] [Related]
6. Cancer: An essential passenger with p53.
Bradner JE
Nature; 2015 Apr; 520(7549):626-7. PubMed ID: 25901678
[No Abstract] [Full Text] [Related]
7. Methylation-induced silencing of ASC and the effect of expressed ASC on p53-mediated chemosensitivity in colorectal cancer.
Ohtsuka T; Liu XF; Koga Y; Kitajima Y; Nakafusa Y; Ha CW; Lee SW; Miyazaki K
Oncogene; 2006 Mar; 25(12):1807-11. PubMed ID: 16331272
[TBL] [Abstract][Full Text] [Related]
8. Novel Wnt signaling and other pathway inhibitors in the colorectal cancer genomic landscape era.
Roukos DH; Ziogas DE; Papaloukas C; Baltogiannis G
Future Oncol; 2012 Nov; 8(11):1373-6. PubMed ID: 23148609
[No Abstract] [Full Text] [Related]
9. Functional repair of p53 mutation in colorectal cancer cells using trans-splicing.
He X; Liao J; Liu F; Yan J; Yan J; Shang H; Dou Q; Chang Y; Lin J; Song Y
Oncotarget; 2015 Feb; 6(4):2034-45. PubMed ID: 25576916
[TBL] [Abstract][Full Text] [Related]
10. Tumor suppressor functions of miR-133a in colorectal cancer.
Dong Y; Zhao J; Wu CW; Zhang L; Liu X; Kang W; Leung WW; Zhang N; Chan FK; Sung JJ; Ng SS; Yu J
Mol Cancer Res; 2013 Sep; 11(9):1051-60. PubMed ID: 23723074
[TBL] [Abstract][Full Text] [Related]
11. AKR1B10, a transcriptional target of p53, is downregulated in colorectal cancers associated with poor prognosis.
Ohashi T; Idogawa M; Sasaki Y; Suzuki H; Tokino T
Mol Cancer Res; 2013 Dec; 11(12):1554-63. PubMed ID: 24140838
[TBL] [Abstract][Full Text] [Related]
12. Is there a role for routine p53 testing in colorectal cancer?
Hoff PM
J Clin Oncol; 2005 Oct; 23(30):7395-6. PubMed ID: 16186590
[No Abstract] [Full Text] [Related]
13. Tumor necrosis factor alpha induces p53 up-regulated modulator of apoptosis expression in colorectal cancer cell lines.
Pastor DM; Irby RB; Poritz LS
Dis Colon Rectum; 2010 Mar; 53(3):257-63. PubMed ID: 20173470
[TBL] [Abstract][Full Text] [Related]
14. Immunoreactivity evaluation of mutant p53 gene product with DNA ploidy pattern in colorectal carcinoma.
Nasif WA; El-Emshaty HM; Tabll A; Elmasry SA; Attallah AM; Gad Elhak NA
Hepatogastroenterology; 2004; 51(58):1001-6. PubMed ID: 15239234
[TBL] [Abstract][Full Text] [Related]
15. p53 gene mutations, p53 protein accumulation and compartmentalization in colorectal adenocarcinoma.
Bosari S; Viale G; Roncalli M; Graziani D; Borsani G; Lee AK; Coggi G
Am J Pathol; 1995 Sep; 147(3):790-8. PubMed ID: 7677190
[TBL] [Abstract][Full Text] [Related]
16. microRNA-16 represses colorectal cancer cell growth in vitro by regulating the p53/survivin signaling pathway.
Ma Q; Wang X; Li Z; Li B; Ma F; Peng L; Zhang Y; Xu A; Jiang B
Oncol Rep; 2013 Apr; 29(4):1652-8. PubMed ID: 23380758
[TBL] [Abstract][Full Text] [Related]
17. [Immunohistochemical detection of p53 in colorectal cancer and its relationship to prognosis].
Yamaguchi A; Fushida S; Kurosaka Y; Kanno M; Yonemura Y; Miyazaki I
Nihon Geka Gakkai Zasshi; 1992 Oct; 93(10):1312-6. PubMed ID: 1435694
[TBL] [Abstract][Full Text] [Related]
18. P53 overexpression and DNA aneuploidy in colorectal adenocarcinomas.
Monaco R; Capasso A; Bellomo PF; Geido E; Giaretti W
Eur J Histochem; 1997; 41 Suppl 2():139-40. PubMed ID: 9859820
[No Abstract] [Full Text] [Related]
19. Biomarkers and targeted therapeutics in colorectal cancer.
Meguerditchian AN; Bullard Dunn K
Surg Oncol Clin N Am; 2013 Oct; 22(4):841-55. PubMed ID: 24012402
[TBL] [Abstract][Full Text] [Related]
20. Allele-specific cancer cell killing in vitro and in vivo targeting a single-nucleotide polymorphism in POLR2A.
Mook OR; Baas F; de Wissel MB; Fluiter K
Cancer Gene Ther; 2009 Jun; 16(6):532-8. PubMed ID: 19165236
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
